---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-052165"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T01:04:35.064105+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Organon Q1 revenue $1.46B (-4% YoY); declares $0.02 dividend; Sun Pharma merger pending

## Summary
- Revenue $1.460B, down 4% as-reported, down 9% ex-FX; Women's Health -16%, Biosimilars +23%.
- GAAP diluted EPS $0.55, Adjusted diluted EPS $0.71; Adjusted EBITDA $415M (28.4% margin).
- Board declares quarterly dividend of $0.02/share, payable June 11 to holders of record May 11.
- Pending all-cash merger with Sun Pharma expected to close early 2027; guidance and earnings calls suspended.
- Net income $146M vs $87M YoY; cash and equivalents $1.12B, debt $8.57B.

## SEC filing metadata
- accession: 0001104659-26-052165
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465926052165/0001104659-26-052165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465926052165/tm2613165d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-052165
- JSON: https://secwatch.observer/filing/0001104659-26-052165.json
- Plain text: https://secwatch.observer/filing/0001104659-26-052165.txt

## Key facts
- Earnings Releases
  Organon & Co. reported quarter ended March 31, 2026 results: revenue $1.460 billion, net income $146 million, EPS $0.55.
  - Period: quarter ended March 31, 2026
  - Revenue: $1.460 billion
  - Net income: $146 million
  - EPS: $0.55
  - Result: reported results
  source text: Organon Reports Results for the First Quarter Ended March 31, 2026 · First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. · First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. · First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821825/000110465926052165/0001104659-26-052165-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.